Boulder Medical Center is pleased to announce that Carolyn Fronczak, MD, has been designated a UroLift® Center of Excellence. The designation recognizes that Dr. Fronczak has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.
Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH.
The UroLift Center of Excellence program is designed to highlight urologists committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.
Over 40 million men in the United States are affected by BPH. This condition occurs when the prostate gland surrounding the male urethra becomes enlarged with advancing age and obstructs the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression, and decreased quality of life.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness, and headaches, prompting many patients to quit using the drugs. The classic alternative is surgery for these patients that cuts, heats, or removes prostate tissue to open the blocked urethra. While current surgical options can effectively relieve symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.
About the UroLift® System
The FDA-cleared UroLift System is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.
Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2.
Patients also experienced a significant improvement in quality of life.
Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.
*No instances of new, sustained erectile or ejaculatory dysfunction
1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016
A Boulder native, Dr. Fronczak attended Sacred Heart of Jesus and Fairview High School. After graduating from Wellesley College, earned a Master’s Degree in Public Health and Medical Doctorate at the University of Colorado. Dr. Fronczak completed her General Surgery and Urologic Surgery Residency at the University of Nebraska.
Dr. Fronczak provides high quality urologic care for both men and women, including a full spectrum of preventive, non-invasive, minimally-invasive and full surgical treatments.